Fresenius | FRE - Equity Capital And Reserves


Fresenius reported EUR19.7B in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
Akzo Nobel EUR 4.85B 28M Jun/2026
Alcon AG USD 22.13B 99M Mar/2026
AstraZeneca USD 50.3B 2.96B Jun/2026
BASF EUR 36.32B 846M Jun/2026
Bayer EUR 28.85B 2.9B Mar/2026
Beiersdorf EUR 8.6B 133M Dec/2025
DaVita Healthcare Partners USD -765.1M 9.6M Jun/2026
Demant DKK 9.84B 446M Dec/2025
E.ON EUR 28.83B 9.57B Mar/2026
Essilor EUR 39.22B 329M Jun/2026
Fresenius EUR 19.7B 766M Jun/2026
Fresenius Medical Care EUR 14.2B 13.95B Mar/2026
Getinge SEK 30.94B 2.06B Jun/2026
Givaudan CHF 4.54B 430M Dec/2025
GlaxoSmithKline GBP 17.64B 223M Jun/2026
GN Store Nord DKK 10.12B 4.76B Mar/2026
GRIFOLS EUR 7.98B 2.52B Jun/2026
Hikma Pharmaceutical USD 2.59B 42M Dec/2025
Lonza CHF 9.13B 513M Dec/2025
Merck EUR 29.74B 1.15B Mar/2026
Novartis USD 41.95B 3.02B Jun/2026
Philips EUR 11.48B 84M Jun/2026
Roche Holding CHF 32.69B 1.11B Jun/2026
RWE EUR 41.56B 3.9B Dec/2025
Sanofi EUR 69.57B 3.24B Jun/2026
Smith & Nephew USD 5.18B 356M Jun/2026